Itb-Med

ITB-MED is developing TCD601 (siplizumab), a CD2-directed monoclonal antibody, for several indications.

Biotechnology Research

Explore the company ↓Explore its lists ↓

Headquarters: New York, United StatesSource: RevenueBaseRetrieved October 13, 2026
Employee range: 11 to 50Source: RevenueBaseRetrieved October 13, 2026
Founded: 2016Source: RevenueBaseRetrieved October 13, 2026
Published list appearances: 11 supported appearances ↗Source: RevenueBase lists

The company at a glance

What does Itb-Med do?

The company focuses on exploring TCD601’s applications in transplantation and autoimmunity. Its clinical trial efforts extend worldwide.

Based on the company’s public LinkedIn information, supplied through RevenueBase.

What the business offers

Services & capabilities.

Monoclonal antibody candidate

ITB-MED is developing TCD601 (siplizumab), described as an antagonistic CD2-directed monoclonal antibody, for several indications.

Source: LinkedIn company description · Retrieved October 13, 2026

Preclinical therapies

ITB-MED is investigating further preclinical therapies.

Source: LinkedIn company description · Retrieved October 13, 2026

Explore the business in context

Company lists.

Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.

#2OF 10

New York

Immunotherapy centers

Snapshot: September 19, 2026

↗

#4OF 22

New York

Clinical-stage biotechnology companies

Snapshot: September 15, 2026

↗

#4OF 16

New York

Immunotherapy research organizations

Snapshot: September 19, 2026

↗

#5OF 21

New York

Biopharmaceutical cell therapy companies

Snapshot: September 15, 2026

↗

#5OF 17

New York

Cell therapy clinical research organizations

Snapshot: October 8, 2026

↗

#7OF 25

New York

Immunotherapy manufacturers

Snapshot: September 15, 2026

↗

#9OF 25

New York

Immunotherapy biotech companies

Snapshot: September 14, 2026

↗

#11OF 25

New York

Immunotherapy companies

Snapshot: September 19, 2026

↗

#12OF 25

New York

Biotherapeutics companies

Snapshot: September 18, 2026

↗

#12OF 25

New York

Immunotherapy developers

Snapshot: September 19, 2026

↗

#15OF 25

New York

Biotech clinical trial organizations

Snapshot: October 7, 2026

↗

Positions describe ordering within each source list. See how lists are built ↗

Share your recognition

Embeddable award for your website

BADGE PREVIEW

Open the published source list.

Itb-Med

#2 Immunotherapy centers

Snapshot: September 19, 2026

Display size

Download SVG

Copy this code into your website

<a href="https://revenuebase.ai/companies/immunotherapy-centers/united-states/new-york" target="_blank" rel="nofollow noopener">
  <img src="https://revenuebase.ai/companies/profiles/itb-med/recognition-companies-immunotherapy-centers-united-states-new-york-20260920-3bd5eec85a68398fa5cff10b1b28ca091ecea8567500ef693ab061320f6c09c2.svg" alt="Itb-Med listed #2 on Immunotherapy centers, September 19, 2026" width="220" height="319" style="max-width:100%;height:auto;" />
</a>

View live list ↗

Sources & data notes.

RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 3, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 14, 2026, September 15, 2026, September 18, 2026, September 19, 2026, October 7, 2026 and October 8, 2026. How the company lists are built.

Help keep this profile accurate

Something changed?

Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.

Request an update ↗

Find your next account

One company is just the start.

Explore more companies by name, headquarters and business focus.

Explore company profiles →